Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)

ZYIL1 is a nucleotide‐binding oligomerization domain, leucine rich repeat and pyrin domain‐containing 3 (NLRP3) inflammasome inhibitor, which prevents NLRP3‐induced apoptosis‐associated speck‐like protein containing a caspase activation and recruitment domain oligomerization, thus inhibiting NLRP3 i...

Descripción completa

Detalles Bibliográficos
Autores principales: Parmar, Deven V., Kansagra, Kevinkumar A., Momin, Taufik, Patel, Hardik B., Jansari, Gaurav A., Bhavsar, Jay, Shah, Chintan, Patel, Jayesh M., Ghoghari, Ashok, Barot, Ajay, Sharma, Bhavesh, Viswanathan, Kasinath, Patel, Harilal V., Jain, Mukul R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087697/
https://www.ncbi.nlm.nih.gov/pubmed/36065092
http://dx.doi.org/10.1002/cpdd.1162

Ejemplares similares

Ejemplares similares